Qlife Holding AB ("Qlife" or the "Company") announces an extension of the non-binding Letter of Intent regarding the potential reverse takeover (the "Transaction") with Hipro Biotechnology Co., Ltd. ( ...

Looking for top-rated stocks to buy now? Recent analyst updates highlight three companies that have earned Strong Buy ratings ...

Investing.com -- Allogene Therapeutics Inc (NASDAQ:ALLO) stock rose 4.9% in after-hours trading on Monday following a favorable arbitration ruling that reaffirmed the company’s control over its cancer ...

Kodiak Sciences focuses on researching, developing, and commercializing therapeutics for retinal diseases. The stock’s decline reflects typical market reaction to potential dilution from new share ...

Krystal Biotech (NASDAQ: KRYS) has outperformed the market over the past 5 years by 19.89% on an annualized basis producing an average annual return of 32.9%. Currently, Krystal Biotech has a market ...

Biotech hot picks highlight stocks focused on lung disease, neurological disorders and rare conditions, with growth driven by ...

Fortress and its majority-owned subsidiary, Cyprium Therapeutics, said the FDA has accepted an NDA resubmission for CUTX-101, or copper histidinate, a treatment for children who suffer from Menkes ...

Trinity Biotech’s next-generation system is designed to strengthen the company’s position in the global laboratory HbA1c market, which is currently estimated to be worth over $2 billion annually and ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

FOXO Technologies Inc. (OTC: FOXO) (the 'Company”), announces Chief Executive Officer Seamus Lagan has provided the following Year-End Review to shareholders: ...

FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics” or the 'Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and ...

For a stock that had been struggling for significance for much of the past year, this dramatic shift was not merely a rally — ...